Cash Flow Statement (Annual)

HUM / Humana, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss 1,040,000 1,099,000 1,419,000 1,222,000 1,231,000 1,147,000 1,276,000 614,000 2,448,000
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Available For Sale Securities Gross Realized Gain Loss Net 20,000 6,000 11,000 33,000 22,000 20,000 146,000 96,000 14,000
    Share Based Compensation 66,000 63,000 67,000 82,000 92,000 98,000 109,000 115,000 157,000
    Depreciation And Amortization 250,000 263,000 303,000 338,000 426,000 449,000 354,000 388,000 410,000
    Amortization Of Intangible Assets 37,000 38,000 54,000 75,000 117,000 121,000 93,000 77,000 75,000
    Increase Decrease In Deferred Income Taxes 27,000 199,000 -22,000 80,000 -42,000 64,000 2,000 71,000 -132,000
    Increase Decrease In Operating Capital
      Increase Decrease In Receivables 60,000 46,000 106,000 -326,000 251,000 264,000 180,000 158,000 -406,000
      Increase Decrease In Other Operating Assets -113,000 -81,000 183,000 253,000 330,000 952,000 872,000 -426,000 582,000
      Increase Decrease In Health Care Insurance Liabilities 17,000 247,000 256,000 -41,000 109,000 582,000 501,000 -413,000 105,000
      Increase Decrease In Other Operating Liabilities 14,000 722,000 194,000 300,000 313,000 413,000 -129,000 937,000 641,000
      Increase Decrease In Deferred Revenue -9,000 -46,000 26,000 -43,000 -24,000 155,000 3,000 -84,000 98,000
      Increase Decrease In Other Operating Capital Net -19,000 -45,000 -61,000 -79,000 -93,000 -42,000 -70,000 -162,000 -155,000
  Net Cash Provided By Used In Operating Activities 1,422,000 2,242,000 2,079,000 1,923,000 1,716,000 1,618,000 868,000 1,936,000 4,051,000
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Businesses Net Of Cash Acquired 12,000 833,000 226,000 1,235,000 187,000 18,000 38,000 7,000 31,000
  Payments To Acquire Property Plant And Equipment 185,000 222,000 346,000 410,000 441,000 528,000 523,000 527,000 526,000
  Payments To Acquire Available For Sale Securities Debt 7,197,000 4,589,000 3,678,000 3,221,000 3,261,000 2,883,000 6,739,000 6,566,000 6,265,000
  Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities 1,271,000 1,821,000 1,569,000 1,497,000 1,077,000 885,000 1,065,000 1,426,000 1,111,000
  Proceeds From Sale Of Available For Sale Securities Debt 3,951,000 2,012,000 1,259,000 1,404,000 1,592,000 2,409,000 5,493,000 4,312,000 2,768,000
  Net Cash Provided By Used In Investing Activities -1,859,000 -1,811,000 -1,358,000 -1,965,000 -1,182,000 -63,000 320,000 -1,362,000 -2,941,000
Net Cash Provided By Used In Financing Activities
  Increase Decrease In Other Deposits - -237,000 -378,000 -397,000 -150,000 -919,000 -296,000 1,093,000 1,823,000
  Proceeds From Issuance Of Senior Long Term Debt - 0 0 990,000 0 1,733,000 0 0 1,779,000
  Proceeds From Repayments Of Commercial Paper - - - - - 0 298,000 -2,000 -153,000
  Increase Decrease In Book Overdrafts 150,000 35,000 -103,000 18,000 79,000 -69,000 -33,000 -89,000 -71,000
  Payments For Repurchase Of Common Stock 23,000 108,000 541,000 518,000 531,000 872,000 385,000 104,000 3,365,000
  Payments Of Dividends 0 0 82,000 165,000 168,000 172,000 172,000 177,000 220,000
  Proceeds From Stock Options Exercised 17,000 -63,000 128,000 57,000 60,000 29,000 23,000 14,000 63,000
  Net Cash Provided By Used In Financing Activities 80,000 -371,000 -1,017,000 -29,000 -702,000 -758,000 -552,000 732,000 -945,000
Cash And Cash Equivalents Period Increase Decrease -357,000 60,000 -296,000 -71,000 -168,000 797,000 636,000 1,306,000 165,000
Cash And Cash Equivalents At Carrying Value - - 1,377,000 1,306,000 1,138,000 1,935,000 2,571,000 3,877,000 4,042,000
Supplemental Cash Flow Information
  Interest Paid 113,000 112,000 114,000 110,000 146,000 143,000 187,000 185,000 216,000
  Income Taxes Paid Net 627,000 785,000 874,000 745,000 734,000 1,030,000 1,179,000 916,000 1,498,000

Peers - Hospital and Medical Service Plans (6324)

Related Articles

HIMX: Himax Technologies Analysis and Research Report

7h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

CUSIP: 444859102